# Journal Pre-proof

Prostate Cancer Outcomes in Patients Living with HIV/AIDS Treated
with Radiation Therapy: A Systematic Review

Tina Vaziri BS , Yuan J. Rao MD , Michael Whalen MD ,
Jeffrey Bethony PhD , Jianqin Lin MD , Sharad Goyal MD

Please cite this article as: Tina Vaziri BS ,   Yuan J. Rao MD ,   Michael Whalen MD ,
 Jeffrey Bethony PhD ,   Jianqin Lin MD ,   Sharad Goyal MD , Prostate Cancer Outcomes in Pa-
tients Living with HIV/AIDS Treated with Radiation Therapy: A Systematic Review, *Advances in
Radiation Oncology* (2022), doi: https://doi.org/10.1016/j.adro.2022.101074

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.

Running title: Radiotherapy Outcomes in HIV and Prostate Cancer

Prostate Cancer Outcomes in Patients Living with HIV/AIDS Treated with Radiation Therapy: A Systematic Review

Tina Vaziri, BS[1]

Yuan J. Rao, MD[1]

Michael Whalen, MD[2]

Jeffrey Bethony, PhD[3]

Jianqin Lin, MD[4]

Sharad Goyal, MD[1]

[1] Department of Radiation Oncology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

[2] Department of Urology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

[3] Department of Department of Microbiology, Immunology & Tropical Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

[4] Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Corresponding Author:

Sharad Goyal, MD

Department of Radiation Oncology

George Washington University

2150 Pennsylvania Ave NW

Washington, DC 20037

202.715.5051 (T)

202.715.5136 (F)

shgoyal@mfa.gwu.edu

Abstract

BACKGROUND: A consensus has not been reached regarding the treatment and outcomes of prostate cancer (PCa) in people living with HIV/AIDS (PLWHA). This systematic review aims to summarize the evidence on the management of PCa with radiation therapy (RT) in PLWHA diagnosed with PCa.

METHODS: Searches were conducted on PubMed, Cochrane Library, and Scopus databases during September 2021 using PRISMA criteria. Articles reporting on outcomes of PLWHA treated for PCa with definitive RT were sought for inclusion.

RESULTS: A total of 9 studies with 187 HIV-positive patients diagnosed with PCa met inclusion criteria. The duration of HIV infection to PCa diagnosis ranged from 8.5-18.6 years with 69- ҃ ҃ku ҃ h ҃ho ҃ from 8-82 ng/mL. Majority of patients (59%) were treated with external-beam RT (EBRT) alone, followed by brachytherapy (BT) (20.5%). The 4- or 5-year biochemical-failure free rate was reported to be between 87-97% in 3 studies and 2 studies reported an 84-

2

97% 5-year cancer-specific survival. Using CTCAE criteria, 3 studies reported toxicities and grade 3 toxicity was observed in only 2 patients.

CONCLUSIONS: RT is efficacious and well tolerated in PLWHA as supported by the comparable biochemical control, clinical outcome, and mortality to the general population as well as by the mild reports of radiotoxicity. There is mixed evidence regarding the effect of RT on CD4 count and viral load and further studies are needed to better understand this relationship. These findings support the use of definitive RT in PLWHA with PCa.

Keywords: Prostate cancer, radiation therapy, HIV, AIDS

Introduction

The development of highly active antiretroviral therapy (HAART) has dramatically altered the disease progression of people living with HIV/AIDS (PLWHA). Historically, AIDS-defining cancers (ADC), such as Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL), were leading causes of morbidity and mortality in PLWHA (1). However, as the life expectancy secondary to HIV complications has improved in the post-HAART era, non-AIDS-defining cancers (NADCs) have become a growing concern for these patients (2). These NADCs include but are not limited to prostate, breast, anal, lung, head and neck, and Hodgkin lymphoma. Epidemiologic data from

3

the HIV/AIDs Cancer Match Study has shown that while the incidence of ADCs has declined threefold from the period of 1995-2005, the incidence of NADCs has conversely risen by threefold (3). In the United States, NADCs comprised 31.4% of all diagnosed cancers in PLWHA from 1991-1995 and have increased to 58.0% with HAART development (4).

Prostate cancer (PCa) is the second most diagnosed cancer in males worldwide and the most diagnosed non-skin malignancy in the United States (5). Its incidence increases with age, and it is more prevalent in the African American population (6). The true incidence of PCa in PLWHA is unknown as contrasting studies have concluded elevated, lowered, or even similar risk compared to the general population (7-9). It has been proposed that previous reports of the lower incidence of PCa in PLWHA can be attributed to discrepancies in PSA screening in this patient group (10).

Advances in surgery, radiation, and chemotherapy have significantly improved the way in which PCa is managed. Despite this, there is a paucity of data describing management and outcomes of PCa in PLWHA. This is of importance as it must be considered whether the pathogenesis of PCa in PLWHA may be influenced by the immune status of patients as well as by the effects of HAART on cancer treatment. Some studies suggest that PCa is more aggressive in PLWHA. For instance, it has been shown that patients do not respond well to androgen deprivation therapy (ADT) as a consequence of the hypogonadal state observed with HIV infection (11).

Other possible mechanisms for altered PCa progression include impaired immune cell surveillance and suppression of cell-mediated immunity.

Currently, PLWHA have the same standard of care treatment options available to them as the general population. These options include surgery, radiation therapy (RT), or active surveillance (AS) for localized, non-metastatic disease. Findings from the recent ProtecT Trial showed low PCa-specific mortality irrespective of these management approaches and lower incidences of disease progression with RT or surgery (12). Among these approaches, RT has the potential to cause genitourinary (GU) and gastrointestinal (GI) toxicity. Further, as RT is known to cause a mild decline in multiple blood cell parameters, including CD4 count, it is unclear if RT could have an additive effect in patients with HIV infection. Historically, PLWHA may have been excluded from participation in many National Cancer Institute (NCI)-sponsored clinical trials, limiting the generalizability of any conclusions to this patient population. Thus, the purpose of this systematic review is to evaluate the clinical outcomes and toxicity of PLWHA diagnosed with PCa treated with definitive RT.

Methods

A literature review was performed that included all the elements of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A comprehensive literature search of PubMed, Scopus, and Cochrane Library databases was performed during

September 2021 with no limit put on the date of publication. The search string contained combinations of Title/Abstract keywords and MeSH terms that are synonyms of human immunodeficiency virus, prostate cancer, and radiotherapy. The full search strategy for these databases is presented in Supplementary Material 1. Eligible studies included randomized control trials, retrospective cohort studies, prospective cohort studies, case-control studies, and review articles presenting new data. References in these publications were examined for other relevant studies. The titles and abstracts of the potentially relevant publications (n = 341) were examined to include only English-language studies that reported outcomes of PCa treated with RT in PLWHA. Among 30 manuscripts that were initially identified for a full review, 9 were selected for inclusion (Table 1). The remaining 21 articles were not included because of the following exclusion criteria: (1) including only patients undergoing prostatectomy; (2) case reports; (3) participating number of patients <5; and (4) paucity of details on clinical outcomes or toxicities.

Qualified studies were then cross-referenced until the search strategy was exhausted. Articles included were published between 2005-2021 and consisted of retrospective studies with the exception of one review article, which also presented previously unpublished data. @   h#
outcomes, and HIV parameters were obtained from the included studies. The results were reviewed by a multidisciplinary team composed of medical, surgical, and radiation oncologists. Critical issues were identified and key findings from the current literature are summarized in this report. The article selection process is summarized in Figure 1.

Results

Patient demographics and characteristics of HIV infection

Table 1 and 2 summarize the patient demographics and the characteristics of HIV infection, respectively. A total of 187 HIV-positive patients were included in 9 studies (13-21). Three articles, which notably have been published in the last 10 years, included a control arm with a total of 1 659 HIV-negative patients (13,15,17). A matched cohort analysis for patient age, race, and tumor stage was performed in 2 of these 3 studies (13,17).

Patient race was reported for 149 patients in 6 of the 9 studies: 118 (79%) African American, 21 (14%) White, 8 (5%) Hispanic, and 2 unknown (1.3%) (13,15,16,17,20,21). Of the 3 studies with a control group, Kahn et al. and Ruden et al. had matched controls (13,17). Meanwhile, Reidel et al. included 1 496 PCa patients from the general population, which had a greater frequency of White patients (52%) and lower frequency of African Americans (45%) compared to HIV-positive patients (15).

As reported in 7 studies, the average duration between HIV infection and PCa diagnosis ranged from 8.5-18.6 years (13,14,15,16,18,20,21). The majority of patients were on HAART at the time of PCa diagnosis (range, 69-100%) and the average CD4

7

count ranged from 336-523 cells/mm³. Viral load at the time of PCa diagnosis showed great variability among patients within the same study and between studies, with a range from undetectable to greater than 100 000 copies/mL. As expected, individual patient data from these studies showed that those who were not receiving HAART had a lower CD4 count, and higher viral load compared to those that were receiving HAART.

Prostate cancer characteristics and therapy

The characteristics of PCa at the time of diagnosis and therapy type are summarized in Table 3. Average patient age at the time of PCa diagnosis ranged from 54-65 years old. Seven studies reported patient PSA levels, with averages ranging from 8-82 ng/mL, while the remaining 2 studies reported that the majority of their patients had PSA levels <10 ng/mL. Gleason staging was provided in 8 studies and most patients had a score of 6 or 7 (range, 2-10). Of the studies that reported the individual clinical T stages of each patient: 69% of patients were T1, 27.4% of patients were T2, 2.4% of patients were T3, and 1.2% of patients were T4. Interestingly, Reidel et al. reported that HIV-positive patients were more likely to present with advanced staged PCa as they found the incidence of Stage III-IV to be 36% in HIV-positive patients versus 14% in the general population (p<0.001) (15).

The type of RT patient received was identified in 127 patients from 8 studies (14-21). Of these, 75 (59%) were treated with EBRT alone, 26 were treated with BT alone (20.5%), and 8 were treated with a combination of EBRT + BT (14%). For patients that received

EBRT alone, the dosage delivered ranged from 72-81 Gy. For those treated with BT alone, 4 patients and one patient received 120 Gy using Palladium-103 and 145 Gy using Iodine-125, respectively (data not shown) (14, 19). Using chi-square analysis, Ruden et al. found that PLWHA with localized disease were more likely to receive definitive RT (59.5% vs. 44.8%) or withhold therapy (13.5% vs. 4.3), and less likely to receive surgery (16.2% vs. 30.2%), than the matched cohort (p = 0.04) (13).

Outcomes

The impact of HIV on RT treatment outcome for PCa was assessed by measurement of follow-up PSA levels, biochemical failure (BCF) rates, and/or mortality and is summarized in Table 4. Since 2006, the definition of BCF has shifted from the ASTRO criteria to the Phoenix criteria, which defines BCF as a rise in 2 ng/mL or more above the nadir PSA (22). Thus, included studies after 2006 used the Phoenix definition when reporting BCF outcomes. Three studies commented on follow-up PSA levels and found that 91% showed declining or stable PSA levels status post-RT treatment (19-21). The 4- or 5-year biochemical-failure free (BFF) rate was reported to be between 87-97% in 3 studies with a combined rate of 94.2% (13,16,17). This was comparable to the 89% and 85% BFF rate found in the HIV-negative control group in the study by Kahn et al. and Ruden et al., respectively (13,17). Ong et al. performed the longest duration of assessment of BCF and found that one patient who was treated with EBRT developed recurrence at 7 years after completion of therapy (14).

9

Mortality was reported in 7 studies. In the studies that contained a cohort of less than 40 HIV-positive patients, no PCa-specific deaths were reported (14,16,17,19,20). The remaining 2 studies found the 5-year cancer-specific survival to be between 74-97% (13,15). Further, Ruden et al. found no difference between the 5-year cancer-specific survival of HIV-positive patients and HIV-negative patients (13). However, through Kaplan-Meier analysis, these authors as well as Reidel et al., found the 5-year overall survival rate to be worse for HIV-positive patients (Table 4) (13,15).

The effects of RT on CD4 count and viral load in PLWHA with PCa are reported in 3 studies with varying results. While Ng et al. found a mean increase from 523 to 577 cells/mm³, Kahn et al. and Schreiber et al. observed a decline in CD4 count in the majority of their patients (Table 5) (16,17,19). However, both groups also noted that all or a majority of their patients showed subsequent improvement in CD4 levels over time following completion of RT (16,17). Kahn et al. did not comment on the time course of CD4 recovery and Schreiber et al. reported recovery at the time of most recent CD4 count, which ranged from 25 to 103 months. Both authors reported that there were no cases of opportunistic infections as a consequence of the temporary increase in immunosuppression. The studies did not specify differences in the change in CD4 count and viral load for those treated with RT alone versus those placed on ADT, however, it appears that only 1 HIV-positive patient in the study by Kahn et al. received ADT (17).

Toxicities

10

There is limited published data on the toxicities/adverse events of RT treatment of prostate cancer in PLWHA. Of the 9 included studies, 3 reported genitourinary (GU) and gastrointestinal (GI) toxicities, which are summarized in Table 5 (16,17,19). All studies utilized the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, a comprehensive grading system for reporting the acute and late effects of cancer treatments.

Kahn et al. found that HIV-positive patients had better tolerance to RT compared to the matched-controls as both reports of acute and chronic GI and GU toxicities were higher in the control groups (p <0.001) (17). The remaining 2 studies did not include control groups; however, both reported mild to moderate toxicities (16,19). Schreiber et al. found that GU toxicity was predominantly limited to less than or equal to grade 2 and both acute and chronic GI toxicity was infrequently reported (16). Two patients reported grade 3 toxicity, 1 of which had a history of urethral stricture and developed recurrence requiring dilations and 1 patient that developed rectal bleeding requiring argon plasma coagulation. Ng et al. had a small cohort of 15 patients, of which 43% reported acute grade 2 GU/GI toxicities and 14% reported chronic grade 2 GU/GI toxicities (19). No patients reported grade 3 or higher GU or GI toxicities. This study also found that 50% of patients reported erectile dysfunction at their most recent follow-up, which declined to 31% by the time of last follow-up with a median follow-up time of 26 months. Finally, the authors also assessed quality of life after RT using the Functional Assessment of Cancer Therapy - General (FACT-G) survey, a 27-item questionnaire that considers

physical, social, emotional, and functional well-being. The mean scores were 83, 80, and 74 for patients of subsets BT, BT+EBRT, and EBRT, respectively, with a total mean score of 80.1 (19).

Discussion

The treatment of cancer in PLWHA is challenging as standards of care are concluded from data of clinical trials that typically exclude HIV-positive patients. To address this knowledge gap, a number of studies have assessed outcomes of these patients compared to the standard recommended treatment for various NADCs. Herein, we summarized the results of such studies that evaluated the outcomes and toxicities in PLWHA with PCa treated with definitive RT. Our review ultimately included 187 HIV-positive patients from 9 studies. No overt disparity in oncologic outcomes for RT in PLWHA was seen, as the BFF survival rate (87-92.3%), mirrored published historical data (85.7% in HIV-negative patients with intermediate-risk PCa) (23). Further, PCa-specific survival rates tend to be favorable in low and intermediate-risk PCa and are comparable to those seen here in PLWHA (24).

While majority of the authors found that the oncological outcomes of RT in HIV-positive patients are similar to that of the HIV-negative general population, Reidel et al. reported higher overall mortality in their cohort of HIV-positive patients. The authors also found that a higher proportion of their patients presented with advanced stage disease (III/IV), which could account for this discrepancy. Indeed, when stratifying HIV-positive patients based on staging, those with stage III/IV disease had worse overall mortality compared stage I/II (15). As this systematic review comprised overwhelmingly of stage I/II disease, the findings of Reidel et

al. highlight the limitation of the other studies and this review to evaluate outcomes of HIV-positive with advanced stage disease. Thus, we are unable to conclude that the outcomes of RT in HIV-positive patients are similar to that of HIV-negative patients in this case. Later stage PCa can require chemotherapy, which may worsen immunosuppression or interact with HIV medication contributing to worse overall mortality. Further studies would be useful to carefully examine outcomes of PLWHA diagnosed with advanced stage PCa.

While this review focuses on the use of RT in HIV-positive patients with PCa, a few published studies have evaluated the outcomes after surgery and have concluded RP to be a safe therapeutic option with similar post-operative related complications to that of HIV-negative patients (25, 26). A retrospective cohort study by Murphy et al. found that HIV-positive patients received significantly less RP and more RT compared to HIV-negative patients (27). Although both RT and RP are considered appropriate therapeutic options, the discrepancy in the use of RP in HIV-positive patients raises curiosity regarding the underlying factors contributing to differences in this treatment pattern.

Concerns regarding the use of RT in PLWHA include radiosensitivity and the development of worse radiotoxicity. A prior study found the expected acute grade 2 rectal toxicity to be 4.5% and acute grade 2 urinary symptoms to be 28% when using intensity-modulated RT in the general population (28). Further, the likelihood of developing chronic grade 2 GU toxicity after RT has been

shown to be around 15% in multiple studies (28,29). Given this, RT is well-tolerated in PLWHA as the rates of chronic grade 2 GI and GU toxicities were comparable to those expected in the general population. Furthermore, there were only a couple reports of grade 3 or higher toxicities in these patients.

Only Ng et al. explored the functional consequences of RT therapy for PCa in PLWHA with the FACT-G survey and found patients to have a mean score of 80.1 with scores of 83, 80, and 74 for patients of subsets BT, BT+EBRT, and EBRT, respectively. This is comparable to the published rates between 66-85% from previous studies that utilized the same survey in PCa patients treated with BT, BT+EBRT, or EBRT alone (30,31,32). Furthermore, both Ng et al. and these studies found that the overall quality of life was lower in patients treated with EBRT alone compared to treatment with BT alone. While Ng et al. did not stratify toxicity data based on treatment modality, previous studies have reported greater rates of GU toxicities with BT, which may account for the reports of lower quality of life in comparison to EBRT (33,34)

The data regarding the effects of RT for PCa on CD4 T-cell count and viral load are limited and were not observed independently of ADT. The studies in this review that reported on this measure had conflicting results with findings of both an increase and decrease in CD4 count. The declines in CD4 count post-RT were also reported to have recovered throughout follow-up in majority of the patients, although the time frame of recovery remains unclear. Calkins et al. recently found that in a study of patients with HIV and a

14

cancer diagnosis, chemotherapy and/or RT resulted in a decline in CD4 count of 203 cells/ L, with every 100 cells/ O˙decrease resulting in a 27% increase in mortality (35). However, as PCa patients were not routinely treated with first-line chemotherapy during the era of the included studies, admittedly this scenario is not entirely applicable. Given these inconclusive findings and the possible effect of worse mortality with declining CD4 count, it is imperative that further studies explore the relationship between CD4 count and RT treatment of PCa in PLWHA. It is also imperative to account/control for the receipt of concomitant ADT.

There are several limitations of our systematic review. First, our search strategy may have missed relevant articles; however, the systematic approach and review by 2 independent reviewers minimized this risk. Second, direct comparison of data was difficult because of the heterogeneity of study designs, settings, and populations across the relevant articles. In addition, the retrospective nature of the relevant articles has inherent limitations, including selection bias and heterogeneity in the reporting of treatment response and adverse events. Finally, a formal meta-analysis was not performed given the heterogeneity in reported outcomes and small sample size of HIV-positive cases. Therefore, the study was largely observational. Nevertheless, these findings are encouraging and as the life expectancy of PLWHA extends with the use of HAART, there is a demand for larger studies evaluating long-term outcomes of PCa in those treated with RT.

In conclusion, the studies reported in this review support the tolerance and efficacy of definitive RT treatment for PCa in PLWHA. Future studies should evaluate the correlation between the safety and efficacy of RT and CD4 cell count, HIV load, PCa treatment selection, and oncologic outcomes for PLWHA. ˚ ˙ ˙V ˙# ˙@ ˙# ˙u ˙- ˙h ˙#u-h ˙ as recently expanded eligibility for enrollment in clinical trials to include HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months, we are hopeful that such studies will soon be more readily achievable.

Data Sharing Statement: **All data generated and analyzed during this study will be provided upon request to the corresponding author**

References

1. Cobucci RN, Lima PH, De Souza PC, Costa VV, de Mesquita Cornetta MD, Fernandes JV, Gonçalves AK. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. Journal of infection and public health. 2015 Jan 1;8(1):1-0.

2. Trickey A, May MT, Vehreschild JJ, Obel N, Gill MJ, Crane HM, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The lancet HIV. 2017 Aug 1;4(8):e349-56.

3. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA. Cancer burden in the HIV-infected population in the United States. Journal of the National Cancer Institute. 2011 May 4;103(9):753-62.

4. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeel TS, Goedert JJ. Cancer risk in people infected with human immunodeficiency virus in the United States. International journal of cancer. 2008 Jul 1;123(1):187-94.

5. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends an update. Cancer Epidemiology and Prevention Biomarkers. 2016 Jan 1;25(1):16-27.

6. Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Reviews in urology. 2008;10(2):111.

7. Sun D, Cao M, Li H, Ren J, Shi J, Li N, Chen W. Risk of prostate cancer in men with HIV/AIDS: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases. 2021 Mar;24(1):24-34.

8. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. American journal of epidemiology. 2007 May 15;165(10):1143-53.

9. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected vs. non-infected patients in the HAART era: impact of immunosuppression. Journal of acquired immune deficiency syndromes (1999). 2009 Oct;52(2):203.

10. Leapman MS, Stone K, Wadia R, Park LS, Gibert CL, Goetz MB, Bedimo R, Rodriguez-Barradas M, Shebl F, Justice AC, Brown ST. Prostate Cancer Screening and Incidence among Aging Persons Living with HIV. The Journal of Urology. 2022 Feb;207(2):324-32.

11. Kwan DJ, Lowe FC. Genitourinary manifestations of the acquired immunodeficiency syndrome. Urology. 1995 Jan 1;45(1):13-27.

12. Hamdy FC, Donovan JL, Lane J, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016 Oct 13;375:1415-24.

18

13. Ruden M, Olivares CH, Fakhoury MQ, Roston A, Vidal PP, Hollowell CMP, et al. Prostate cancer presentation, treatment selection, and outcomes among men with HIV/AIDS: A clinical stage, race, and age-matched contemporary analysis. Urol Oncol 2021 Jan;39(1):73.e19-73.e25.

14. Ong WL, Manohar P, Millar J, Royce P. Clinicopathological characteristics and management of prostate cancer in the human immunodeficiency virus (HIV)-positive population: experience in an Australian major HIV centre. BJU Int 2015 Oct;116 Suppl 3:5-10.

15. Riedel DJ, Cox ER, Stafford KA, Gilliam BL. Clinical presentation and outcomes of prostate cancer in an urban cohort of predominantly African American, human immunodeficiency virus-infected patients. Urology 2015 Feb;85(2):415-421.

16. Schreiber D, Chhabra A, Rineer J, Nabhani T, Katsoulakis E, Morkos R, et al. Outcomes and tolerance of human immunodeficiency virus--positive U.S. veterans undergoing dose-escalated external beam radiotherapy for localized prostate cancer. Clin Genitourin Cancer 2014 Apr;12(2):94-99.

17. Kahn S, Jani A, Edelman S, Rossi P, Godette K, Landry J, et al. Matched cohort analysis of outcomes of definitive radiotherapy for prostate cancer in human immunodeficiency virus-positive patients. Int J Radiat Oncol Biol Phys 2012 May 1;83(1):16-21.

18. Wosnitzer MS, Lowe FC. Management of prostate cancer in HIV-positive patients. Nat Rev Urol 2010 Jun;7(6):348-357.

19

19. Ng T, Stein NF, Kaminetsky J, Berman S, Marans HY, McDermott B, et al. Preliminary results of radiation therapy for prostate cancer in human immunodeficiency virus-positive patients. Urology 2008 Nov;72(5):1135-8; discussion 1138.

20. Pantanowitz L, Bohac G, Cooley TP, Aboulafia D, Dezube BJ. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. BJU Int 2008 Jun;101(12):1519-1523.

21. Levinson A, Nagler EA, Lowe FC. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology 2005 Jan;65(1):91-94.

22. Roach III M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology* Biology* Physics. 2006 Jul 15;65(4):965-74.

23. Vassil AD, Murphy ES, Reddy CA, Angermeier KW, Altman A, Chehade N, Ulchaker J, Klein EA, Ciezki JP. Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology. 2010 Nov 1;76(5):1251-7.

24. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?. European journal of cancer. 2012 Jul 1;48(11):1664-71.

25. Huang WC, Kwon EO, Scardino PT, Eastham JA. Radical prostatectomy in patients infected with human immunodeficiency virus. BJU international. 2006 Aug;98(2):303-7.

26. Izadmehr S, Leapman M, Hobbs AR, Katsigeorgis M, Nabizada-Pace F, Jazayeri SB, Samadi DB. Clinical characteristics and outcomes of HIV-seropositive men treated with surgery for prostate cancer. International urology and nephrology. 2016 Oct;48(10):1639-45.

27. Murphy AB, Bhatia R, Martin IK, Klein DA, Hollowell CM, Nyame Y, Dielubanza E, Achenbach C, Kittles RA. Are HIV-infected men vulnerable to prostate cancer treatment disparities?. Cancer Epidemiology, Biomarkers & Prevention. 2014 Oct;23(10):2009-18.

28. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. International Journal of Radiation Oncology* Biology* Physics. 2002 Aug 1;53(5):1111-6.

29. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology* Biology* Physics. 2008 Mar 15;70(4):1124-9.

30. U   ˙VO˙"   ˙-˚˙"   ˙k˙‡   ˙K˙u   ˙)˙@ ˙ ˙ ˙   ˙   ˙   ˙   ˙   ˙   ˙   deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2003 Mar 1;97(5):1203-10.

31. Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology. 2000 May 1;55(5):736-42.

32. Martínez E, Garin O, Pardo Y, Fernández P, Guix B, Gutiérrez C, Boladeras A, Ferrer F, Hernández T, Ayala A, Egiguren M. Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study. Journal of Contemporary Brachytherapy. 2021 Feb;13(1):1.

33. Zelefsky MJ, Yamada Y, Pei X, Hunt M, Cohen G, Zhang Z, Zaider M. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology. 2011 Apr 1;77(4):986-90.

34. Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE. Quality of life after surgery, external beam   ˙ ˙   ˙   ˙   ˙   ˙   ˙   ˙#   ˙   ˙K˙   -47.

35. Calkins KL, Chander G, Joshu CE, Visvanathan K, Fojo AT, Lesko CR, Moore RD, Lau B. Immune status and associated mortality after cancer treatment among individuals with HIV in the antiretroviral therapy era. JAMA oncology. 2020 Feb 1;6(2):227-35.

22

Figure 1. PRISMA flow diagram representing the approach to identification, screening, eligibility, and inclusion of articles

Table 1 | Study and Patient Characteristics

Study	Country	Cohort size, *n*		Study Period	Average age at PCa Dx (range)		Race			Outcomes Measured
		HIV[+]	HIV[-]		HIV[+]	HIV[-]	HIV[+]		HIV[-]	
Levinson et al. 2005[21]	USA	10	NA	NR	54 (41-69)	NA	AA (*n*=6, 60%) White (*n*=2, 20%) His (*n*=, 20%)		NA	Change in PSA post-treatment
Ng et al. 2008[19]	USA	14	NA	2000-2006	61 (49-71)	NA	NR		NA	Change in PSA post-treatment, FACT-G quality of life, mortality, change in HIV parameters, toxicities
Pantanowitz et al. 2008[20]	USA	17	NA	1996-2006	59 (46-76)	NA	AA (*n*=3, 18%) White (*n*=8, 47%) His (*n*=2, 12%) Haitian (*n*=1, 6%) Un (*n*=3, 18%)		NA	Biochemical recurrence, mortality
Wosnitzer et al. 2010[18]	USA	11	NA	NR	NR	NA	NR		NA	Biochemical recurrence
Kahn et al. 2012[17,*]	USA	13	26	1999-2009	55 (44-74)	60 (50-73)	AA (*n*=10, 77%) White (*n*=3, 23%)		AA (*n*=20, 77%) White (*n*=6, 23%)	BFF survival, mortality, change in HIV parameters, toxicities
Schreiber et al. 2014[16,*]	USA	15	NA	2003-2010	65	NA	AA (*n*=12, 80%) White (*n*=1, 7%) His (*n*=2, 13%)		NA	BFF survival, mortality, change in HIV parameters, toxicities
Ong et al. 2015[14]	Australia	12	NA	2000-2015	62.7 (46-79)	NA	NR		NA	BFF survival, mortality
Reidel et al. 2015[15,*]	USA	49	1496	2000-2011	60.7	64	AA (92%) White (8%)		AA (45%) White (52%) NR (3%)	Differences in PCa staging between HIV[+] and HIV[-], mortality
Ruden et al. 2021[13,*]	USA	46	137	2000-2016	57.2	58.2	AA (*n*=41, 89%) White (*n*=3, 7%) His (*n*=2, 4%)		AA (*n*=122, 89%) White (*n*=8, 6%) His (*n*=7, 5%)	BFF survival, castration-resistance survival, PCa-specific mortality, overall mortality

* Median is reported instead of the mean for average
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ku

Abbreviations: BFF, biochemical-failure free, PCa, prostate cancer, AA, African American, His, Hispanic, NA, not applicable, NR, not reported, Un, unknown

Table 2 | Characteristics of HIV Infection				
Study	% Receiving HAART	Average duration years of HIV infection (range)	Average CD4 T-cell count per mm^3 (range)	Average viral load, RNA copies/ mL (range)
Levinson et al. 2005[21]	90	8.75 (0.5-19)	417 (76-1070)	UD (n=5, 50%) 141.67 (50-106,000)
Ng et al. 2008[19]	79	NR	523(200-946)	UD (n=9, 64%) (UD-27,000)
Pantanowitz et al. 2008[20]	82	8.5 (2-20)	336 (24-759)	17,319 (0->100,000)
Wosnitzer et al. 2010[18]	100	EBRT: 18.6 (14-22) BT 10.8 (6-17)	EBRT: 437 (76-1070) BT: 1417 (454-4117)	EBRT: 255 (25-501) BT: 12.5 (UD-50)
Kahn et al. 2012[17]	69	NR	412.3 (50-1002)	UD (n=5, 38%) (UD-20,718)
Schreiber et al. 2014[16]	87	9.8 (1-21)	464.2 (138-994)	UD (n=11, 73%)
Ong et al. 2015[14]	100	11.9	485 (235-1116)	UD (67%)
Reidel et al. 2015[15]*	82	10.5	391 (301-634, IQR)	400 (n=37, 76%)
Ruden et al. 2021[13]*	91	8.63	400.5 (254-581, IQR)	40 (40-124, IQR)

* Median is reported instead of the mean for average
† ⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞ =°°ku⁞⁞⁞⁞⁞⁞ copies/mL
⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞⁞ 2 patients were diagnosed with HIV 1 and 3 years after PCa diagnosis and duration of HIV infection is unknown for 2 patients
Abbreviations: HAART, highly antiretroviral therapy, EBRT, external beam radiation therapy, BT, brachytherapy, UD, undetectable, HIV, human immunodeficiency virus, NR, not reported, IQR, interquartile range

Table 3| Prostate Cancer Characteristics and Treatment Details						
Study	Pretreatment average or % PSA, *n*g/mL (range)	Mean Gleason Score, *n* or % (range)	AJCC Prostate Stage or Anatomic Stage		Therapy Type, n or %	
			HIV⁺	HIV⁻	HIV⁺	HIV⁻
Levinson et al. 2005[21]	9.2 (4.5-19.9)	6; GS 5 (20%) GS 6 (60%) GS 7 (20%)	T1c (70%) T2a (20%) T2b (10%)	NA	BT (20%) EBRT (30%) RP (10%) CS (10%) ADT (10%) WW (20%)	NA
Ng et al. 2008[19]	14.3 (0-77)	6.5; GS 6 (57%) GS 7 (36%) GS 8 (7%)	T1c (43%) T2b (36%) T2c (21%)	NA	EBRT (14%) BT (29%) EBRT + BT (57%)	NA
Pantanowitz et al. 2008[20]	30 (4.5-77)	6.8 (6-8)	pT1c (41%) pT2 (12%) pT3 (6%) NR (41%)	NA	EBRT + ADT (41%) BT (18%) RP (18%) 2 ADT (12%) WW (6%)	NA
Wosnitzer et al. 2010[18]	ERBT: 8 BT: 10	NR	T1c (82%) T2a (9%) T2b (9%)	NA	ERBT (27%) BT (36%) RP (36%)	NA
Kahn et al. 2012[17]	< 10 (85%) 10-20 (15%) > 20 (0%)	GS <7 (46%) GS 7 (46%) GS >7 (8%)	T1c (77%) T2a (15%) T2c (8%)	T1c (77%) T2a (19%) T2c (4%)	EBRT (100%): 3D-CRT (54%) IMRT (46%)	EBRT (100%): 3D-CRT (54%) IMRT (46%)
Schreiber et al. 2014[16]	< 10 (73%) 10.1-20 (20%) > 20 (7%)	GS 2-6 (20%) GS 7 (47%) GS 8-10 (33%)	T1c (80%) T2a (7%) T2b (7%) T3b (7%)	NA	EBRT (100%): 3D-CRT (*n*=7) IMRT (*n*=8) Adj ADT (*n*=5)	NA
Ong et al. 2015[14]*	11.1 (3.9-269)	GS 6 (33%) GS 7 (33%) GS 8 (8%) GS 9 (25%)	T1c (58%) T2a (8%) T2c (17%) T4 (17%)	NA	EBRT (42%) BT (8%) EBRT+ADT (8%) CS+ADT+EBRT (8%) RP (17%) AS (17%)	NA

26

Reidel et al. 2015[15]	82 (2.5-1830)	7 (5-10)	I (14%) II (49%) III (18%) IV (18%) T1-2 (*n*=34, 70%) T3-4 (*n*=15, 30%)	I (5%) II (68%) III (7%) IV (7%) Unknown (13%) T Stage NR	EBRT (51%) BT (25%) Orchiectomy (4%) RP (22%) Chemo (12%) WW (10%)	NR
Ruden et al. 2021[13*]	HIV+ 10.5 (3.9-24.5, IQR) HIV- 10.6 (6.4-22.5, IQR)	GS 6 (53%) GS 7 (30%) GS 8-10 (10%)	T1c (47.6%) T2 (40%) T3 (4.8%) T4 (7.1%)	T1c (55.9%) T2 (38.2%) T3 (3.7%) T4 (2.2%)	RT (56.5%) ADT (4.3%) RP (17.4%) AS (8.7%) None (13%)	RT (38.7%) ADT (16.7%) RP (27%) AS (13.9%) None (3.7%)

* Median is reported instead of the mean for average
˚o   ˙7
accounted for
Abbreviations: 3D-CRT, three-dimensional conformal radiation therapy, ADT, androgen deprivation therapy, Adj, adjuvant, AS, active surveillance, BT, brachytherapy, Chemo, chemotherapy, CS, cryosurgery, EBRT, external beam radiation therapy, IMRT, intensity-modulated radiation therapy, NA, not applicable, NR, not reported, RP, radical prostatectomy, WW, watchful waiting

27

Table 4 | Prostate Cancer Outcomes and Mortality			
Study	Median follow-up duration, years (range)	PCa Outcomes	Mortality
Levinson et al. 2005[21*]	2.3 (1.4-3)	PSA < baseline (*n*=8, 100%); PSA <1.5 ng/mL (*n*=4, 50%); Stable PSA with WW (*n*=2, 100%)	NR
Ng et al. 2008[19]	2.17 (.67-6.1)	PSA 1.1 ng/mL (*n*=13, 93%); PSA increased (*n*=1)[**]; Mean FACT-G score: 80.1, BT: 83, BT + EBRT: 80, EBRT: 74 (48-104, range)	PCa-specific (*n*=0); Heart failure (*n*=1), 15 months post-RT
Pantanowitz et al. 2008[20]	NR	Undetectable PSA and no tumor recurrence (*n*=17, 100%)	PCa-specific (*n*=0); Urosepsis (*n*=1) HIV encephalopathy (*n*=1); Cirrhosis (*n*=1); Unknown (*n*=2)
Wosnitzer et al. 2010[18]	EBRT: 5 BT: 6.25 RP: 1.54	EBRT: Stable PSA (mean, 1.36 ng/mL) and no recurrence (*n*=3, 100%); BT: PSA <0.1 ng/mL (*n*=2, 50%), lost to follow-up (*n*=1)	NR
Kahn et al. 2012[17]	3.25 (.25-9.17)	No difference in 4-year BFF survival between HIV[+] (87%) and HIV[-] patients (89%). (*p* = 0.94)	HIV[+] total deaths (*n*=0); HIV[-] total deaths (*n*=2) from PCa-nonspecific causes
Schreiber et al. 2014[16]	4.08 (2.08-8.58)	5-year BFF survival (92.3%); BCR 28 months and 63 months post-treatment (*n*=2)	PCa-specific (*n*=0); Cholangiocarcinoma (*n*=1), 35 months post-RT
Ong et al. 2015[14]	3.83 (.75-8.58)	EBRT: BCR 7 years post-RT (*n*=1, 20%) BT: 5-year BFF survival (*n*=1, 100%)	PCa-specific (*n*=0); Anal cancer (*n*=1) Ischemic heart disease (*n*=2)
Reidel et al. 2015[15]	HIV[+]: 2.7 (1.4-3.9, IQR) HIV[-]: NR	NR	HIV[+] total deaths (n=13, 27%); 5-year PCa-specific survival (74%); HIV[-] total deaths (n=342, 22%); Worse overall mortality in HIV[+] patients (*p* = 0.006)
Ruden et al. 2021[13]	3.9, (2.1-5.6, IQR)	No difference in 5-year BFF survival between HIV[+] (97%) and HIV[-] patients (85%) (HR 0.89, *p* = 0.84)	No difference in PCa-specific mortality (HR 2.99, *p* = 0.83); Worse risk of mortality in HIV[+] patients (HR 2.89, *p* = 0.04)
* Mean is reported instead of the median for follow-up duration ** Patient with increased PSA post-treatment was found to have metastasis Abbreviations: BFF, biochemical failure-free, BCR, biochemical recurrence, BT, brachytherapy, EBRT, external-beam radiation therapy, HR, hazard-ratio, IQR, inter-quartile range, NR, not reported, PCa, prostate cancer, PSA, prostate-specific antigen, RP, radical prostatectomy, WW, watchful waiting			

Table 5 | Radiation Effect on HIV Parameters and Toxicities

Study	Effect on CD4 count	Effect on viral load	Genitourinary Acute	Chronic	Gastrointestinal Acute	Chronic
Ng et al. 2008[19]	Stable (*n*=13, 93%); Declined (*n*=1, 7%)	Stable (*n*=12, 86%); Increased (*n*=2, 14%)	Grade II (*n*=6, 43%)	Grade II (*n*=2, 14%)	Grade II (*n*=6, 43%) Diarrhea (*n*=5, 36%)	Grade II (*n*=2, 14%)
Kahn et al. 2012[17]	Declined (*n*=11, 85%); Mean decline 193 cells/mm³, (42-498, range); All had recovery of CD4 count	Increased (*n*=7, 54%); Declined (*n*=5, 38%); UD (*n*=3, 23%)	Greater in HIV⁻ patients (p<0.001); No acute toxicity in 46% HIV⁺ vs. 4% HIV⁻; Grade III toxicity in 0% HIV⁺ vs. 4% HIV⁻ patients	Greater in HIV⁻ patients (p<0.001); No chronic toxicity in 62% HIV⁺ vs. 30% HIV⁻ patients	Greater in HIV⁻ (p=0.003); No acute toxicity in 46% HIV⁺ vs. 30% HIV⁻; No acute grade III in HIV⁺ or HIV⁻ patients	Greater in HIV⁻ patients (p<0.001); No chronic toxicity in 75% HIV⁺ vs. 58% HIV⁻; Grade III toxicity in 0% HIV⁺ vs. 15% HIV⁻ patients
Schreiber et al. 2014[16]	Declined (*n*=8, 89%) ; Most had recovery of CD4 count	NR	Grade I (*n*=4, 27%) Grade II (*n*=5, 33%) Grade III (*n*=1, 7%)	Grade II (*n*=2, 13%) Grade III (*n*=1, 7%)	Grade I (*n*=4, 27%))	Grade 3 (*n*=1, 7%)

#) ` was measured throughout radiation therapy treatment in 9 out of the 15 patients
Toxicity grading performed using the Common toxicity criteria (CTCAE) version 3.0 grading system for genitourinary and gastrointestinal complications
Abbreviations: NR, not reported